Illumina (ILMN)

What Moves the Stock

1. 01Consumable revenue growth and instrument utilization rates (pull-through per instrument), indicating installed base productivity and end-market demand strength
2. 02NovaSeq X adoption trajectory and competitive positioning against emerging long-read sequencing technologies (PacBio, Oxford Nanopore)
3. 03Clinical diagnostics revenue growth, particularly multi-cancer early detection tests and liquid biopsy adoption rates in oncology
4. 04Regulatory developments affecting genomic testing reimbursement (FDA oversight of laboratory-developed tests, CMS coverage decisions)
5. 05China revenue exposure (historically 15-20% of sales) and geopolitical risks affecting instrument exports and consumable demand
6. 06Consumables (reagents, flow cells, library prep kits): approximately 65-70% of revenue, recurring high-margin sales tied to installed base utilization
7. 07Sequencing instruments (NovaSeq X, NextSeq 2000): approximately 20-25% of revenue, capital equipment sales with 3-5 year replacement cycles
8. 08Services and other (maintenance contracts, array products): approximately 10-15% of revenue

ILMN Chart

My Notes

• growth - Illumina attracts investors seeking exposure to the structural growth of genomics applications across precision medicine…
• Rising interest rates negatively impact Illumina through two channels: (1) biotech/pharma customers face higher capital costs…
• Watch on earnings: NovaSeq X instrument placements per quarter and consumable pull-through rates (revenue per instrument annually), Clinical diagnostics revenue growth rate and oncology testing partnership announcements (GRAIL separation impact), China revenue trends and geographic diversification progress amid geopolitical tensions.